The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Open accessAbstract
Lung adenocarcinoma, the most common subtype of non-small cell lung cancer, is responsible for more than 500,000 deaths per year worldwide. Here, we report exome and genome sequences of 183 lung adenocarcinoma tumor/normal DNA pairs. These analyses revealed a mean exonic somatic mutation rate of 12.0 events/megabase and identified the majority of genes previously reported as significantly mutated in lung adenocarcinoma. In addition, we identified statistically recurrent somatic mutations in the splicing factor gene U2AF1 and truncating mutations affecting RBM10 and ARID1A. Analysis of nucleotide context-specific mutation signatures grouped the sample set into distinct clusters that correlated with smoking history and alterations of reported lung adenocarcinoma genes. Whole-genome sequence analysis revealed frequent structural rearrangements, including in-frame exonic alterations within EGFR and SIK2 kinases. The candidate genes identified in this study are attractive targets for biological characterization and therapeutic targeting of lung adenocarcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [23]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [62]
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [62]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Circos: An information aesthetic for comparative genomicsPreprint
Krzywinski, M. I., Schein, J. E., Birol, İ., Connors, J. M., Gascoyne, R. D., Horsman, D. E., Jones, S. J. M., & Marra, M. A. (2009) · Genome Research · doi:10.1101/gr.092759.109 · Cited by 11,073
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Self-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,000
miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1
Su, W., Mo, Y., Wu, F., Guo, K., Li, J., Luo, Y., Ye, H., Guo, H., Li, D., & Yang, Z. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.09.027 · Cited by 50
BAFfling pathologies: Alterations of BAF complexes in cancer
Arnaud, O., Loarer, F. L., & Tirode, F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.046 · Cited by 46
Wang, Y., Li, N., Jiang, W., Deng, W., Ye, R., Cai, X., Qiao, Y., Sharma, A., Zhang, M., Hung, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1489 · Cited by 46
Elman, J. S., Ni, T. K., Mengwasser, K. E., Jin, D. X., Wronski, A., Elledge, S. J., & Kuperwasser, C. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.060 · Cited by 47
Passaro, A., Attili, I., Rappa, A., Vacirca, D., Ranghiero, A., Fumagalli, C., Guarize, J., Spaggiari, L., de Marinis, F., Barberis, M. C. P., et al. (2021) · Cancers · doi:10.3390/cancers13092172 · Cited by 46
Targeting Epigenetics in Lung CancerPreprint
Chao, Y. L., & Pecot, C. V. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038000 · Cited by 49
Yang, Q., Li, B., Ge, X., Yang, S., Wang, P., Tang, H., & Liu, Y. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27886 · Cited by 46
Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma
Alam, M., Hasan, G. M., Eldin, S. M., Adnan, M., Riaz, M. B., Islam, A., Khan, I., & Hassan, M. I. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114452 · Cited by 52
Yu, Y., & He, J. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0272-4 · Cited by 46
Evolving techniques for gene fusion detection in soft tissue tumours
Mertens, F., & Tayebwa, J. (2013) · Histopathology · doi:10.1111/his.12272 · Cited by 47
Dorr, C. R., Janik, C. L., Weg, M. T., Been, R. A., Bader, J. M., Kang, R. J. D., Ng, B., Foran, L. A., Landman, S. R., O’Sullivan, M. G., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0674-t · Cited by 46
Yang, L., Gao, Q., Shi, J.-Y., Wang, Z., Zhang, Y., Gao, P., Wang, X., Shi, Y., Ke, A., Shi, G., et al. (2015) · Hepatology · doi:10.1002/hep.28149 · Cited by 46
DNA Sequencing of Cancer: What Have We Learned?
Chmielecki, J., & Meyerson, M. M. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-060712-200152 · Cited by 48
Self-citationWhole exome sequencing of rare aggressive breast cancer histologies
Dieci, M. V., Smutná, V., Scott, V., Yin, G., Xu, R., Vielh, P. R., Mathieu, M., Vicier, C., Laporte, M., Drusch, F., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3718-y · Cited by 46
ATM protein is deficient in over 40% of lung adenocarcinomas
Villaruz, L. C., Jones, H., Đačić, S., Abberbock, S. R., Kurland, B. F., Stabile, L. P., Siegfried, J. M., Conrads, T. P., Smith, N. R., O’Connor, M. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9757 · Cited by 46
Maury, E., & Hashizume, R. (2017) · Epigenetics · doi:10.1080/15592294.2016.1278095 · Cited by 50
Nakagomi, T., Goto, T., Hirotsu, Y., Shikata, D., Yokoyama, Y., Higuchi, R., Amemiya, K., Okimoto, K., Oyama, T., Mochizuki, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24365 · Cited by 46
Xu, S., Zheng, Y., Zhang, L., Wang, P., Niu, C., Wu, T., Tian, Q., Yin, X., Shi, S., Zheng, L., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.08.005 · Cited by 46
Drug-sensitiveFGFR3 mutations in lung adenocarcinoma
Chandrani, P., Prabhash, K., Prasad, R., Sethunath, V., Ranjan, M., Iyer, P. S., Aich, J., Dhamne, H., Iyer, D. N., Upadhyay, P., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw636 · Cited by 46
Pisapia, P., Pepe, F., Iaccarino, A., Sgariglia, R., Nacchio, M., Russo, G., Gragnano, G., Malapelle, U., & Troncone, G. (2020) · Cells · doi:10.3390/cells9122549 · Cited by 44
Dervovic, D., Malik, A., Chen, E. L. Y., Narimatsu, M., Adler, N., Afiuni‐Zadeh, S., Krenbek, D., Martinez, S., Tsai, R., Boucher, J. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38841-7 · Cited by 48
Miyazaki, I., Odintsov, I., Ishida, K., Lui, A. J. W., Kato, M., Suzuki, T., Zhang, T., Wakayama, K., Kurth, R. I., Cheng, R., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00630-y · Cited by 45
Zhang, P., Yang, Z., Zuo, L., Zhang, G., Zhang, L., Zhang, Z., & Fan, J. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18408 · Cited by 46
The diverse oncogenic and tumor suppressor roles of salt-inducible kinase (SIK) in cancer
Du, W., Zheng, J., & Pei, D. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1101452 · Cited by 45
Long Noncoding RNA-LET Suppresses Tumor Growth and EMT in Lung Adenocarcinoma
Liu, B., Pan, C., He, Z., Wang, J., Wang, P.-L., Ma, T., Xia, Y., & Chen, Y. (2016) · BioMed Research International · doi:10.1155/2016/4693471 · Cited by 45
Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosis
Hwang, J. A., Kim, D., Chun, S., Bae, S., Song, J. S., Kim, M. Y., Koo, H. J., Song, J. W., Kim, W. S., Lee, J. C., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4978 · Cited by 46
RBM10: Harmful or helpful‐many factors to consider
Loiselle, J. J., & Sutherland, L. C. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26644 · Cited by 45
Kerr, K. M., Dafni, U. G., Schulze, K., Thunnissen, E., Bubendorf, L., Hager, H., Finn, S. P., Biernat, W., Vliegen, L., Hernández‐Losa, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx629 · Cited by 44
Yi, M., Li, T., Qin, S., Yu, S., Chu, Q., Li, A., & Wu, K. (2020) · BioMed Research International · doi:10.1155/2020/4169691 · Cited by 46
Targeting BRD9 for Cancer Treatment: A New Strategy
Zhu, X., Liao, Y., & Tang, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s286867 · Cited by 45
Zhou, M., Yuan, J., Deng, Y., Fan, X., & Shen, J. (2021) · Oncogenesis · doi:10.1038/s41389-020-00296-6 · Cited by 49
Yang, S., Huang, Y., & Zhao, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878740 · Cited by 50
MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
Smida, M., Fece de la Cruz, F., Kerzendorfer, C., Uras, I. Z., Mair, B., Mazouzi, A., Suchankova, T., Konopka, T., Katz, A. M., Paz, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13701 · Cited by 44
“The high frequency of ATM mutation in this collection (12 out of 93 cell lines, Supplementary Dataset 2) was similar to that previously reported in patients 2,4,5 .”
InfluentialLiquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma
Song, Z., Cai, Z., Yan, J., Shao, Y. W., & Zhang, Y. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.14 · Cited by 43
Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis
Kadry, Y. A., Lee, J.-Y. L., & Witze, E. S. (2021) · Open Biology · doi:10.1098/rsob.210033 · Cited by 44
Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress
Zhang, S., Duan, S., Xie, Z., Bao, W., Xu, B., Yang, W., & Zhou, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.924817 · Cited by 50
Bland, P. J., Saville, H., Wai, P. T., Curnow, L., Muirhead, G., Nieminuszczy, J., Ravindran, N., John, M. B., Hedayat, S., Barker, H. E., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01460-5 · Cited by 48
Krishnan, V. G., Ebert, P. J., Ting, J. C., Lim, E. H., Wong, S. S., Teo, A. S. M., Yue, Y. G., Chua, H.-H., Ma, X., Loh, G. S. L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3195 · Cited by 45
Shilo, A., Siegfried, Z., & Karni, R. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.970955 · Cited by 45
Yeddula, N., Xia, Y., Ke, E., Beumer, J., & Verma, I. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520110112 · Cited by 43
Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
Yarden, Y., & Wheeler, D. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2 · Cited by 44
Campos, B., de Castro, J., Massutí, B., Vicente‐Baz, D., Parente, D. P., Gracia, P. R., Crama, L., & Cobo, M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13681 · Cited by 46
Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer
Yan, J., Kang, D. D., Turnbull, G., & Dong, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114042 · Cited by 45
Gong, Z., Jia, Q., Chen, J., Diao, X., Gao, J., Wang, X., & Zhu, B. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.024 · Cited by 43
Tan, D. S. W., Camilleri‐Broët, S., Tan, E. H., Alifano, M., Lim, W., Bobbio, A., Zhang, S., Ng, Q., Ang, M., Iyer, N. G., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28750 · Cited by 43
Zakharova, V., Magnitov, M. D., Maestro, L. D., Ulianov, S. V., Glentis, A., Uyanik, B., Williart, A., Karpukhina, A. A., Demidov, O. N., Joliot, V., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac234 · Cited by 46
GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies
Benbarche, S., Pineda, J. M. B., Galvis, L. D. B., Biswas, J., Liu, B., Wang, E., Zhang, Q., Hogg, S. J., Lyttle, K. A., Dahi, A., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.04.006 · Cited by 45
Development of Lung Adenocarcinomas with Exclusive Dependence on Oncogene Fusions
Saito, M., Shimada, Y., Shiraishi, K., Sakamoto, H., Tsuta, K., Totsuka, H., Chiku, S., Ichikawa, H., Kato, M., WATANABE, S.-I. I., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3282 · Cited by 43
Eggermont, A. M. M., Robert, C., Soria, J., & Zitvogel, L. (2014) · OncoImmunology · doi:10.4161/onci.27560 · Cited by 43
Pernemalm, M., Petris, L. D., Branca, R. M., Forshed, J., Kanter, L., Soria, J., Girard, P., Validire, P., Yudi Pawitan, Y., van den Oord, J., et al. (2013) · Journal of Proteome Research · doi:10.1021/pr4002096 · Cited by 44
Genomic Sequencing for Cancer Diagnosis and Therapy
Wang, L., & Wheeler, D. A. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-120811-171056 · Cited by 44
Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis
Schuster, K., Venkateswaran, N., Rabellino, A., Girard, L., Peña‐Llopis, S., & Scaglioni, P. P. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0620-t · Cited by 43
DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma
Berger, A. H., Chen, M., Morotti, A., Janas, J. A., Niki, M., Bronson, R. T., Taylor, B. S., Ladanyi, M., Aelst, L. V., Politi, K. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079526 · Cited by 43
Self-citationRNA structure in splicing: An evolutionary perspective
Lin, C., Taggart, A. J., & Fairbrother, W. G. (2016) · RNA Biology · doi:10.1080/15476286.2016.1208893 · Cited by 44
Treating KRAS -mutant NSCLC: latest evidence and clinical consequences
Garrido, P., Olmedo, M. E., Gómez, A., Ares, L. P., López‐Ríos, F., Rosa-Rosa, J. M., & Palacios, J. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017719829 · Cited by 45
Role of RNF20 in cancer development and progression – a comprehensive review
Sethi, G., Shanmugam, M. K., Arfuso, F., & Kumar, A. P. (2018) · Bioscience Reports · doi:10.1042/bsr20171287 · Cited by 44
In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer
Grzeskowiak, C. L., Kundu, S. T., Mo, X., Ivanov, A. A., Zagorodna, O., Lu, H., Chapple, R. H., Tsang, Y. H., Moreno, D., Mosqueda, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04572-3 · Cited by 44
Computing the Role of Alternative Splicing in Cancer
Liu, Z., & Rabadán, R. (2021) · Trends in cancer · doi:10.1016/j.trecan.2020.12.015 · Cited by 43
Blijlevens, M., Li, J., & van Beusechem, V. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105110 · Cited by 43
Tang, S., Xue, Y., Qin, Z., Fang, Z., Sun, Y., Yuan, C., Pan, Y., Zhao, Y., Tong, X., Zhang, J., et al. (2023) · National Science Review · doi:10.1093/nsr/nwad028 · Cited by 40
Self-citationRoper, J., Sinnamon, M. J., Coffee, E. M., Belmont, P. J., Keung, L., Richard, L. G., Wang, W. V., Faber, A. C., Yun, J., Yilmaz, Ö. H., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.018 · Cited by 42
Suzuki, A., Mimaki, S., Yamane, Y., Kawase, A., Matsushima, K., Suzuki, M., Goto, K., Sugano, S., Esumi, H., Suzuki, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073484 · Cited by 43
Li, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1870 · Cited by 42
Loiselle, J. J., Roy, J. G., & Sutherland, L. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180258 · Cited by 43
SPP1 and AGER as potential prognostic biomarkers for lung adenocarcinoma
Zhang, W., Fan, J., Chen, Q., Lei, C., Qiao, B., & Liu, Q. (2018) · Oncology Letters · doi:10.3892/ol.2018.8235 · Cited by 42
Li, W., Zhang, G., Li, X., Wang, X., Li, Q., Hong, L., Shen, Y., Zhao, C., Gong, X., Chen, Y., et al. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.129 · Cited by 42
Pu, X., Wang, J., Li, W., Fan, W., Wang, L., Mao, Y., Yang, S., Liu, S., Xu, J., Lv, Z., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.006 · Cited by 42
Devecchi, A., Cecco, L. D., Dugo, M., Penso, D., Dagrada, G. P., Brich, S., Stacchiotti, S., Sensi, M., Canevari, S., & Pilotti, S. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0339-3 · Cited by 42
Caiola, E., Falcetta, F., Giordano, S., Marabese, M., Garassino, M. C., Broggini, M., Pastorelli, R., & Brunelli, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0954-5 · Cited by 41
UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells
Liu, Z., & Xu, L. (2018) · BMB Reports · doi:10.5483/bmbrep.2018.51.12.138 · Cited by 43
Screening Approaches for Targeting Ribonucleoprotein Complexes: A New Dimension for Drug Discovery
D’Agostino, V., Sighel, D., Zucal, C., Bonomo, I., Micaelli, M., Lolli, G., Provenzani, A., Quattrone, A., & Adami, V. (2019) · SLAS DISCOVERY · doi:10.1177/2472555218818065 · Cited by 44
Xu, Q., Wang, C., Zhou, J., Xu, Z.-M., Gao, J., Sui, P., Walsh, C. P., Ji, H., & Xu, G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107599119 · Cited by 41
Zhao, X., Wang, A., Walter, V., Patel, N. M., Eberhard, D. A., Hayward, M. C., Salazar, A. H., Jo, H., Soloway, M. G., Wilkerson, M. D., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129280 · Cited by 44
Identification and Characterization of Oncogenic SOS1 Mutations in Lung Adenocarcinoma
Cai, D., Choi, P. S., Gelbard, M., & Meyerson, M. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0316 · Cited by 41
Self-citationPatterns and Mutational Signatures of Tandem Base Substitutions Causing Human Inherited Disease
Chen, J., Férec, C., & Cooper, D. N. (2013) · Human Mutation · doi:10.1002/humu.22341 · Cited by 38
Shimoni-Sebag, A., Lebenthal-Loinger, I., Zender, L., & Karni, R. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt247 · Cited by 42
Sabari, J. K., Santini, F. C., Bergagnini, I., Lai, W. V., Arbour, K. C., & Drilon, A. E. D. C. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0587-4 · Cited by 42
Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC
Yang, Y., Wang, X., Yang, J., Duan, J., Wu, Z., Yang, F., Zhang, X., & Xiao, S. (2019) · Cancer Management and Research · doi:10.2147/cmar.s207329 · Cited by 41
Tracing Lung Cancer Risk Factors Through Mutational Signatures in Never-Smokers
Landi, M. T., Synnott, N. C., Rosenbaum, J., Zhang, T., Zhu, B., Shi, J., Wei, Z., Kebede, M., Sang, J., Choi, J., et al. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa234 · Cited by 41
Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer
Vichas, A., Riley, A. K., Nkinsi, N. T., Kamlapurkar, S., Parrish, P. C. R., Lo, A., Duke, F. F., Chen, J., Fung, I., Watson, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24841-y · Cited by 43
Self-citationRole of CBL Mutations in Cancer and Non-Malignant Phenotype
Leardini, D., Messelodi, D., Muratore, E., Baccelli, F., Bertuccio, S. N., Anselmi, L., Pession, A., & Masetti, R. (2022) · Cancers · doi:10.3390/cancers14030839 · Cited by 42
Guanine holes are prominent targets for mutation in cancer and inherited disease
Bacolla, A., Temiz, N. A., Yi, M., Ivanic, J., Cer, R. Z., Donohue, D. E., Ball, E. V., Mudunuri, U. S., Wang, G., Jain, A., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003816 · Cited by 40
ALKBH5-mediated m6A demethylation of lncRNA RMRP plays an oncogenic role in lung adenocarcinoma
Yu, H., & Zhang, Z. (2021) · Mammalian Genome · doi:10.1007/s00335-021-09872-6 · Cited by 40
Ethanol-Induced Cell Damage Can Result in the Development of Oral Tumors
Hoes, L., Dok, R., Verstrepen, K. J., & Nuyts, S. (2021) · Cancers · doi:10.3390/cancers13153846 · Cited by 38
Peng, S., Sen, B., Mazumdar, T., Byers, L. A., Diao, L., Wang, J., Tong, P., Giri, U. P., Heymach, J. V., Kadara, H. N., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6376 · Cited by 40
Jao, K., Tomasini, P., Kamel‐Reid, S., Korpanty, G. J., Mascaux, C., Sakashita, S., Labbé, C., Leighl, N. B., Liu, G., Feld, R. D., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.023 · Cited by 40
The genomic landscape of nonsmall cell lung carcinoma in never smokers
Boeckx, B., Shahi, R. B., Smeets, D., Brakeleer, S. D., Decoster, L., Brussel, T. V., Galdermans, D., Vercauter, P., Decoster, L., Alexander, P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32797 · Cited by 40
Kohsaka, S., Hayashi, T., Nagano, M., Ueno, T., Kojima, S., Kawazu, M., Shiraishi, Y., Kishikawa, S., Suehara, Y., Takahashi, F., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.021 · Cited by 41
Hung, Y. P., Redig, A. J., Hornick, J. L., & Sholl, L. M. (2020) · Modern Pathology · doi:10.1038/s41379-020-0592-2 · Cited by 41
Moreno-Rodriguez, T., Monterde, B., González-Silva, L., Betancor-Fernández, I., Revilla, C., Agraz-Doblás, A., Freire, J., Marrón, P. I., Quevedo, L., Blanco, R. E., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01748-y · Cited by 43
RNA-binding proteins in pluripotency, differentiation, and reprogramming
Guallar, D., & Wang, J. (2014) · Frontiers in Biology · doi:10.1007/s11515-014-1326-y · Cited by 39
Vanni, I., Coco, S., Truini, A., Rusmini, M., Bello, M. G. D., Alama, A., Banelli, B., Mora, M., Rijavec, E., Barletta, G., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226129 · Cited by 39
An RRM–ZnF RNA recognition module targets RBM10 to exonic sequences to promote exon exclusion
Collins, K. M., Kainov, Y. A., Christodoulou, E., Ray, D., Morris, Q., Hughes, T. R., Taylor, I. A., Makeyev, E. V., & Ramos, A. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx225 · Cited by 39
O’Brien, T., Jia, P., Caporaso, N. E., Landi, M. T., & Zhao, Z. (2018) · Genome Medicine · doi:10.1186/s13073-018-0522-9 · Cited by 39
Characterization of genetic alterations in brain metastases from non‐small cell lung cancer
Liao, L., Ji, X., Ge, M., Zhan, Q., Huang, R., Liang, X., & Zhou, X. (2018) · FEBS Open Bio · doi:10.1002/2211-5463.12501 · Cited by 39
Shimomura, I., Yokoi, A., Kohama, I., Kumazaki, M., Tada, Y., Tatsumi, K., Ochiya, T., & Yamamoto, Y. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.002 · Cited by 42
Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence
Xu, X., Liu, Q., Zhang, C., Ren, S., Xu, L., Zhao, Z., Dou, H., Li, P., Zhang, X., Gong, Y., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1521-5 · Cited by 38
Han, X., Tan, Q., Yang, S., Li, J., Xu, J., Hao, X., Hu, X., Xing, P., Liu, Y., Lin, L., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00556 · Cited by 39
Miyanaga, A., Masuda, M., Motoi, N., Tsuta, K., Nakamura, Y., Nishijima, N., WATANABE, S.-I. J., Asamura, H., Tsuchida, A., Seike, M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.027 · Cited by 39
A synthetic small molecule stalls pre-mRNA splicing by promoting an early-stage U2AF2-RNA complex
Chatrikhi, R., Feeney, C. F., Pulvino, M. J., Alachouzos, G., MacRae, A. J., Falls, Z., Rai, S., Brennessel, W. W., Jenkins, J. L., Walter, M. J., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.007 · Cited by 38
Metadata
- Authors
- Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., Sougnez, C., Auclair, D., Lawrence, M. S., Stojanov, P., Cibulskis, K., Choi, K., de Waal, L., Sharifnia, T., Brooks, A., Greulich, H., Banerji, S., Zander, T., Seidel, D., Leenders, F., Ansén, S., Ludwig, C., Engel-Riedel, W., Stoelben, E., Wolf, J., Goparju, C., Thompson, K., Winckler, W., Kwiatkowski, D., Johnson, B. E., Jänne, P. A., Miller, V. A., Pao, W., Travis, W. D., Pass, H. I., Gabriel, S. B., Lander, E. S., Thomas, R. K., Garraway, L. A., Getz, G., & Meyerson, M.
- Affiliations
- Broad Institute (US)
- Samsung Medical Center (KR)
- NYU Langone Health (US)
- Dana-Farber Cancer Institute (US)
- University of Cologne (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Vanderbilt University (US)
- Corresponding author
- Meyerson, Matthew
- ORCID
- Imielinski, Marcin
- Berger, Alice H.
- Hammerman, Peter S.
- Hernandez, Bryan
- Pugh, Trevor J.
- Hodis, Eran
- Cho, Jeonghee
- Suh, James
- Capelletti, Marzia
- Sivachenko, Andrey
- Auclair, Daniel
- Lawrence, Michael S.
- Cibulskis, Kristian
- Sharifnia, Tanaz
- Brooks, Angela
- Greulich, Heidi
- Banerji, Shantanu
- Zander, Thomas
- Seidel, Danila
- Stoelben, Erich
- Wolf, Jürgen
- Winckler, Wendy
- Kwiatkowski, David
- Johnson, Bruce E.
- Miller, Vincent A.
- Pao, William
- Travis, William D.
- Pass, Harvey I.
- Gabriel, Stacey B.
- Lander, Eric S.
- Thomas, Roman K.
- Garraway, Levi A.
- Getz, Gad
- Meyerson, Matthew
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 150
- Issue
- 6
- Pages
- 1107-1120
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC3557932
- OpenAlex
- W2042386784
- Cited by
- 1,789
- References
- 79
- Citations by year
- 2026: 38 · 2025: 66 · 2024: 81 · 2023: 94 · 2022: 124 · 2021: 128 · 2020: 155 · 2019: 131 · 2018: 138 · 2017: 138 · 2016: 145 · 2015: 187 · 2014: 199 · 2013: 148 · 2012: 14
- FWCI
- 141.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 380 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Max Planck Institute for Plasma Physics (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Broad Institute
- Canadian Institutes of Health Research
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (R01CA109038, R01CA116020, T32 CA9216, P50CA090578, T32CA009216)
- National Institute of General Medical Sciences (T32 GM07753, T32GM007753)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, mutational signatures, U2AF1, RBM10, ARID1A, structural rearrangement, EGFR, SIK2, smoking history, cancer genomics, therapeutic target
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Cohort Studies, Genes, Neoplasm, Genome-Wide Association Study, High-Throughput Nucleotide Sequencing, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
